Email this article 
Clinical and biochemical features of some intravenous iron complexes
- Authors: Abashin S.Y.1, Misyurina E.N.2, Zhelnova E.I.3, Misyurin A.V.1
-
Affiliations:
- Dmitriy Rogachev Federal Research Centre of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
- Consultation and Diagnostic Centre “Genotechnologya”
- Hematological Research Center, Ministry of Health of Russia
- Issue: Vol 8, No 3 (2013)
- Pages: 55-59
- Section: PHARMACOTHERAPY
- Published: 21.08.2013
- URL: https://oncohematology.abvpress.ru/ongm/article/view/27
- DOI: https://doi.org/10.17650/1818-8346-2013-8-3-55-59
- ID: 27
Cite item
Full Text
Abstract
Most anemia cases associated with iron deficiency. There are various therapeutic approaches to compensate iron deficiency. In some cases,
a rapid restore of body iron is required, which is only possible with intravenous administration. Now a number of intravenous iron preparations are available, and each of them has not only advantages. Considering the drugs side effects, there was a need for drugs with high efficiency, low immunogenicity, and minimal toxicity. One of the decisions was to create preparations based on maltose and isomaltose. Such new intravenous iron preparations are ferric carboxymaltose and iron isomaltoside. Currently, there are no available clinical data that isomaltose and maltose preparations differ significantly with respect to adverse reactions associated with their immunogenicity. Based on study results isomaltose preparations in patients with dextran sensibilization should be used with caution. This is not completely exclude the possibility that both of these drugs can be an immune response trigger with a different specificity than the one on dextran develops. Preparations based on maltose, sucrose and gluconate were neutral in immunoprecipitation assay with dextran-reactive antibodies that determines their preference for patients with dextran sensibilisation. Other important properties of ferric carboxymaltose are: convenience of application and lack of oxidative stress that are determined by the slow iron release.
Keywords
About the authors
S. Yu. Abashin
Dmitriy Rogachev Federal Research Centre of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
Author for correspondence.
Email: sergabash@mail.ru
Russian Federation
E. N. Misyurina
Consultation and Diagnostic Centre “Genotechnologya”Russian Federation
E. I. Zhelnova
Hematological Research Center, Ministry of Health of RussiaRussian Federation
A. V. Misyurin
Dmitriy Rogachev Federal Research Centre of Pediatric Hematology, Oncology and Immunology, Ministry of Health of RussiaRussian Federation
References
Supplementary files
